Lv56
1130 积分 2025-03-17 加入
Thyroid hormone receptor-beta agonists: new MASLD therapies on the horizon
1个月前
已完结
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis
1个月前
已完结
Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies
1个月前
已完结
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis
1个月前
已完结
Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study
1个月前
已完结
A GLP-1 receptor agonist semaglutide attenuates cardiac microvascular injury in HFD/STZ-induced diabetic mice
1个月前
已完结
Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD
2个月前
已完结
Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis
2个月前
已完结
White adipocyte dysfunction and obesity-associated pathologies in humans
2个月前
已完结
Obesity drugs aren’t always forever. What happens when you quit?
2个月前
已完结
皖公网安备34019202002308
